Tuesday, July 27, 2021 3:13:48 PM
Hookipa Pharma (HOOK)
Next up, Hookipa Pharma, is another clinical-stage immune-oncology research firm. Hookipa uses a proprietary platform to modify arenaviruses to carry virus-specific and tumor-specific genes directly to the patient’s T-cells, thus ‘educating’ the immune system to create the correct response. The company is using this approach to develop treatments for several serious viral diseases, including CMV, HBV, and HIV, as well as HPV-related cancer and prostate cancer.
The company has two leading research tracks. On the infectious disease front, HB-101 is a potentially prophylactic treatment against CMV – a vaccine candidate. HB-101 is currently in Phase 2 clinical trial and enrolling patients. Safety and efficacy data is expected to start coming in during 2H21.
The company also has several drug candidates in Phase 1 trials against HPV-related cancers. This is a dangerous class of cancers affecting women, and connected to the human papillomavirus. The company initiated trials for HB-201 and HB-202 late last year. Data release this past May showed acceptable safety and tolerability factors. In June, Hookipa released data on HB-200, another of its anti-cancer drug candidates. The candidate showed only 18% overall response rate – but showed antigen-specific CD8+ T cell responses described as ‘outstanding.’
Despite these ongoing trials and early data, the company’s stock plunged in June. H.C. Wainwright analyst Swayampakula Ramakanth believes the selloff was unwarranted.
“In our view, the sell-off is likely due to the lower than expected efficacy data from the cohort receiving HB-202/HB-201 alternating treatment…. However, we believe it is premature to make the call. First, all eight patients enrolled in HB-202/HB-201 cohort to date remain on the treatment, and only four of them are evaluable for efficacy, of whom, one patient achieved target tumor shrinkage of nearly 20%. Additionally, preliminary data on antigen-specific CD8+ T cells are consistent with the preclinical data. Finally, the company is still escalating the dose level for HB-202/ HB-201, and there were no dose-limiting toxicities and no Grade ≥3 treatment-related adverse events observed,” Ramakanth noted.
The analyst summed up, “Taken together, we believe HB-202/HB-201 alternating treatment still holds the potential to deliver stronger efficacy compared to HB-201 monotherapy, and the recent sell-off creates an attractive entry point for long-term investors.”
In line with these comments, the analyst rates HOOK a Buy, and his $21 price target implies a one-year upside potential of ~181%. (To watch Ramakanth’s track record, click here)
That Wall Street likes this stock is clear from the unanimous Strong Buy consensus rating. That consensus is built on 4 recent Buy reviews, which is good news for HOOK. The share are priced at $7.48 and their $23.33 average price target implies ~212%.
https://www.tipranks.com/news/article/3-strong-buy-stocks-trading-at-rock-bottom-prices-2/
Recent HOOK News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2024 12:04:58 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/08/2024 09:27:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 09:15:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:32:12 PM
- HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 08/08/2024 08:30:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 08/02/2024 10:38:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/26/2024 08:08:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 08:17:16 PM
- HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200 • GlobeNewswire Inc. • 07/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2024 11:00:16 AM
- HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split • GlobeNewswire Inc. • 07/08/2024 11:01:00 AM
- HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV • GlobeNewswire Inc. • 07/01/2024 08:31:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:15:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:15:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:15:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:15:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 08:03:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 08:15:13 PM
- HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting • GlobeNewswire Inc. • 06/04/2024 05:00:44 PM
- HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting • GlobeNewswire Inc. • 05/30/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 09:05:13 PM
- HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting • GlobeNewswire Inc. • 05/23/2024 09:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 11:04:49 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:03:13 AM
- HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 05/09/2024 11:01:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM